Understanding GLP-1 Receptor Agonist Impact Beyond Weight Loss
GLP-1 receptor agonist body composition changes extend beyond simple weight loss, impacting skin, muscle, and overall patient care. These changes require clinicians to address new patient concerns and coordinate multidisciplinary care. Understanding…
Tirzepatide vs Dulaglutide: Cardiorenal Outcomes Study
This article reviews tirzepatide cardiorenal outcomes from the SURPASS-CVOT study, highlighting its advantages over dulaglutide. Tirzepatide shows superior cardiovascular and renal protection in type 2 diabetes patients. These findings support…
GLP-1 Diabetes Cardiovascular Outcomes & Medicare 2026
Medicare GLP-1 coverage 2026 will expand access to important diabetes and cardiovascular medications. This change requires clinicians to manage GLP-1 therapy as a long-term treatment. Understanding cardiovascular outcomes is critical for patient…
GLP-1 Receptor Agonist Evidence: 20% Heart Attack Risk Drop
GLP-1 receptor agonist cardiovascular outcomes safety data reveal a 20% reduction in heart attack risk. Semaglutide's cardioprotective effects extend beyond glucose control. Medicare Part D coverage expansion in 2026 improves access for high-risk…